2026/9/10 On behalf of subsidiary Tianjin Chase Sun Jiandakang, PTS-302 NDA was accepted for review in Morocco.

1.Date of occurrence of the event:2026/09/09

2.Company name: Tianjin Chase Sun Jiandakang Pharmaceutical Technology Co., Ltd.

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):subsidiaries

4.Reciprocal shareholding ratios:80.91%

5.Cause of occurrence: Our 80.91%-owned subsidiary, Tianjin Chase Sun Jiandakang Pharmaceutical Technology Co., Ltd. (hereinafter referred to as ”Tianjin Jiandakang”), and Company I jointly filed the New Drug Application (NDA) for PTS-302, a lung cancer treatment product. On September 9, 2026, the Moroccan competent authority officially notified us of its acceptance of the NDA application.

6.Countermeasures:None

7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The development of new drugs is a lengthy and costly process, and there is no no guarantee of success. These factors may expose investments to risks. Investors should carefully assess the risks and exercise caution when making investments.